Condition 1: Overweight and obesity. Condition 2: Postmenopausal atrophic vaginitis. Condition 3: Age-related osteoporosis. Condition 4: Sarcopenia. Condition 5: cardiometabolic health. Condition 6: Body composition. Condition 7: Cognitive function. Condition 8: Mood disorders. Condition 9: Sleep disorders. Condition 10: Dry, itchy skin and wrinkling. Condition 11: Genitourinary Syndrome of Menopause (GSM). Condition 12: ]nflammation. Overweight and obesity Postmenopausal atrophic vaginitis A
Conditions
Interventions
Intervention 1: Intervention group: Daily intermittent fasting (16:8, from 19:00 to 11:00)
. Intervention 2: Intervention group 2: Fasted state moderate-intensity continuous exercise training (45-90 min training at 9 am following 14 h of fasting, 3 days/week)
. Intervention 3: Intervention group 3: Fed state moderate-intensity continuous exercise training (45-90 min training at 9 am, 2 h after breakfast, 3 days/week)
. Intervention 4: Intervention group 4: Fasted state high-intensity interval training (45-90 min training at 9 am following 14 h of fasting, 3 days/week)
. Intervention 5: Intervention group 5: Fed state high-intensity interval training (45-90 min training at 9 am, 2 h after breakfast, 3 days/week)
. Intervention 6: Control group: no nutritional and exercise intervention.
Sponsors
International Science and Technology University
Eligibility
Sex/Gender
Female
Age
50 Years to 70 Years
Inclusion criteria
Inclusion criteria: Female 50 years 70 Body mass index > 25 kg/m2 > 3 years after the final period Not engaged in regular exercise activities over the last six months No smoking or alcohol consumption
Exclusion criteria
Exclusion criteria: Suffering from chronic cardiovascular, liver and kidney diseases Having any pain or mobility limitations that prevent interventions. Current treatment with medication or supplements that significantly affect the main study variables. Having a history of bariatric surgery Following a special diet, including strict vegetarian/vegan, within the past 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Body composition. Timepoint: Before and after 12 weeks of intervention as well as following a 3-month follow-up. Method of measurement: By Dual-Energy X-ray Absorptiometry (DXA).;Genitourinary Syndrome of Menopause (GSM). Timepoint: Before and after 12 weeks of intervention as well as following a 3-month follow-up. Method of measurement: Vaginal Health Index (VHI) Questionnaire, Day-to-Day Impact of Vaginal Aging (DIVA) Questionnaire, Vulvovaginal Symptoms Questionnaire (VSQ), Female Sexual Function Index (FSFI) Questionnaire, The Genital Health Clinical Evaluation (GHCE) Questionnaire, Transvaginal Ultrasound, Bladder Diary and Pad Test. | — |
Secondary
| Measure | Time frame |
|---|---|
| Mood. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using the Menopause-Specific Quality of Life Questionnaire, Patient Health Questionnaire-9, and Generalized Anxiety Disorder-7 questionnaire.;Bone mineral density. Timepoint: Before and after 12 weeks of intervention, as well as after a 3-month follow-up. Method of measurement: By Dual-Energy X-ray Absorptiometry (DXA).;Muscle strength. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using one repetition maximum test and digital strength measuring devices.;Resting metabolic rate. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Indirect calorimetry.;Cognitive function. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using functional tests to assess executive function, memory, processing speed, and attention.;Plasma levels of irisin. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using ELISA method.;Insulin resistance. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using fasting glucose, HOMA-IR, and HbA1c measurements.;Lipid profile. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Biochemical analysis.;Plasma levels of brain-derived neurotrophic factor. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using ELISA method.;Plasma levels of beta-hydroxybutyrate. Timepoint: Before and after training sessions (1 session per week). Method of measurement: Using ELISA method.;Oxidative stress. Timepoint: Before and after 12 weeks of intervention, as well as after 3-month follow-up. Method of measurement: Using | — |
Countries
Turkey
Contacts
Public ContactDavar Khodadadi
Islamic Azad University
Outcome results
None listed